We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0VQA market cap is 0. The company's latest EPS is USD -0.8587 and P/E is -75.61.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.69M | -42.66M | -55.68M | -70.36M | -100.83M |
| Net Income | -25.78M | -39.5M | -54.99M | -68.87M | -85.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 284.26M | 256.5M | 210.66M | 168.53M | 368.49M |
| Total Liabilities | 7.14M | 12.16M | 8.78M | 23.21M | 20.07M |
| Total Equity | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -24.75M | -21.78M | -47.59M | -48.4M | -73.38M |
| Investing | 7.46M | 41.57M | 37.96M | 54.75M | -179.09M |
| Financing | 887k | 950k | 6.88M | 4.16M | 271.38M |
| Market Cap | 0 |
| Price to Earnings Ratio | -75.61 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 116.99 |
| Price to Book Ratio | 18.64 |
| Dividend Yield | - |
| Shares Outstanding | 100.03M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Viking Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.vikingtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
